anti-CD22 chimeric antigen receptor T cells

Anti-CD22 chimeric antigen receptor (CAR) T cells are an investigational autologous or allogeneic cell therapy engineered to target the CD22 antigen, a surface glycoprotein expressed on mature B-cells and most B-cell malignancies. This therapy is primarily developed for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), particularly in patients who have failed CD19-targeted therapies or experienced CD19 antigen escape. Beijing Boren Hospital has been a leading institution in the clinical development of these cells, often utilizing them in sequential or cocktail administration protocols alongside CD19 CAR-T cells to improve durable remission rates. The CAR construct typically consists of an anti-CD22 single-chain variable fragment (scFv) coupled with costimulatory domains such as 4-1BB (CD137) and the CD3-zeta signaling chain, which facilitate T-cell activation and cytotoxic activity against CD22-positive leukemia cells.

Other names

anti-CD22 chimeric antigen receptor T cellsanti-CD-22 chimeric antigen receptor T cellsanti-CD 22 chimeric antigen receptor T cellsCD22 CAR-T cellsCD-22 CAR-T cellsCD 22 CAR-T cellsCD22-directed CAR-T cellsCD-22-directed CAR-T cellsCD 22-directed CAR-T cells